Sobre as alterações no crédito imobiliário e outras referentes à política habitacional contidas na MP 2.212 de 30/8/01 e nas MPs 2.221 e 2.223 de 4/9/01

Consultoria Legislativa - Área VII - Finanças, Direito Comercial, Direito Econômico, Defesa do Consumidor - Área XI - Meio Ambiente, Geografia, Urbanismo, Arquitetura.

Diário da Constituinte [gravação de vídeo] : [programa n. 223]

Continua o impasse na Assembleia Nacional Constituinte sobre o sistema de governo. O Relator da Comissão de Sistematização da Assembleia Nacional Constituinte (ANC), Deputado Bernardo Cabral (PMDB-AM) ainda não se decidiu entre o presidencialismo, parlamentarismo puro e híbrido. O Deputado Manoel Moreira (PMDB-SP) declara que a preocupação é encontrar um sistema que tenha condições de governabilidade ao país. Cidadãos opinam sobre o tema. O Relator Bernardo Cabral declara sua opinião sobre o parlamentarismo. O Deputado Theodoro Mendes (PMDB-SP) apresenta proposta mantendo o presidencialismo, mas com o fortalecimento do Legislativo. A emenda do Senador Nelson Carneiro (PMDB-RJ) adota o parlamentarismo, mas dá ao presidente o poder de exonerar o primeiro-ministro. O Deputado Cid Carvalho (PMDB-MA) tenta o consenso, com a proposta do parlamentarismo adotado de forma gradual e mandato de seis anos para o Presidente José Sarney. O Senador Fernando Henrique Cardoso (PMDB-SP) admite a necessidade de um período de adaptação, mas não de dois ou três anos. O Deputado Victor Faccioni (PDS-RS) defende o parlamentarismo.

C 223 Artesana mostrando su proceso de trabajo de talla en madera. (Casanare)

7 fotografías a color.

M. Couperus, L’Etude des périodiques anciens, Colloque d’Utrecht (Paris 1972), 223 p.

info:eu-repo/semantics/published

A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer

BACKGROUND: Patients with castration-resistant prostate cancer (CRPC) and bone metastases have an unmet clinical need for effective treatments that improve quality of life and survival with a favorable safety profile. OBJECTIVE: To prospectively evaluate the efficacy and safety of three different doses of radium chloride (Ra 223) in patients with CRPC and bone metastases. DESIGN, SETTING, AND PARTICIPANTS: In this phase 2 double-blind multicenter study, 122 patients were randomized to receive three injections of Ra 223 at 6-wk intervals, at doses of 25 kBq/kg (n=41), 50 kBq/kg (n=39), or 80 kBq/kg (n=42). The study compared the proportion of patients in each dose group who had a confirmed decrease of =50% in baseline prostate-specific antigen (PSA) levels. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Efficacy was evaluated using blood samples to measure PSA and other tumor markers, recorded skeletal-related events, and pain assessments. Safety was evaluated using adverse events (AEs), physical examination, and clinical laboratory tests. The Jonckheere-Terpstra test assessed trends between groups. RESULTS AND LIMITATIONS: The study met its primary end point with a statistically significant dose-response relationship in confirmed =50% PSA declines for no patients (0%) in the 25-kBq/kg dose group, two patients (6%) in the 50-kBq/kg dose group, and five patients (13%) in the 80-kBq/kg dose group (p=0.0297). A =50% decrease in bone alkaline phosphatase levels was identified in six patients (16%), 24 patients (67%), and 25 patients (66%) in the 25-, 50-, and 80-kBq/kg dose groups, respectively (p

Bone-targeting radiopharmaceuticals including radium-223

ABSTRACT: Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphonate and strontium-89 have been used for decades in the palliation of pain from bone metastases especially from prostate cancer. Emerging evidence of improved survival in metastatic castration-resistant prostate cancer (CRPC) with the first-in-class a-radionuclide, radium-223 (Ra) has rekindled interest in the role of bone-seeking radionuclide therapy.We review the literature for randomized controlled trials of bone-seeking radionuclides and explore some of the issues regarding the optimal use of these agents. In particular, we discuss dose, dose rate, radiobiology, and quality of radiation and postulate on potential future directions in particular combination schedules. ß-Emitting, bone-seeking radionuclides have proven ability to control pain in prostate cancer metastatic to bone with pain response rates in the order of 60% to 70% when used as single agents. Most of the published trials were underpowered to detect differences in survival; however, there is evidence of the potential for disease modification when these agents are used in combination with chemotherapy or in multiple cycles.Data from the recent phase III ALSYMPCA trial that compared Ra to placebo in symptomatic CRPC demonstrate a significant improvement in median overall survival of 3.6 months for patients with symptomatic CRPC metastatic to bone treated with 6 cycles of the a-emitting radionuclide Ra compared with placebo. The success of Ra in improving survival in CRPC will lead this agent to become part of the treatment paradigm for this disease, and with such an excellent safety profile, Ra has huge potential in combination strategies as well as for use earlier in the natural history of metastatic prostate cancer.

Alpha emitter radium-223 and survival in metastatic prostate cancer

Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.